Avasimibe Pfizer.

Avasimibe Pfizer.

Current opinion in investigational drugs (London, England : 2000) (2002-12-25)

John R Burnett, Murray W Huff

RESUMEN

Avasimibe (also known as CI-1011 or PD-148515) is a selective acyl-coenzyme A:cholesterol O-acyltransferase (ACAT) inhibitory lipid-regulating agent under development by Pfizer (formerly Parke-Davis) for the potential treatment of hyperlipidemia and atherosclerosis. The compound is currently undergoing phase III clinical trials [371470].

MATERIALES

Referencia del producto

Marca

Descripción del producto

PZ0190

Sigma-Aldrich

Avasimibe, ≥98% (HPLC)